Trial Profile
A Phase IIIB, 24-week Randomised, Double-blind Study to Compare 'Closed' Triple Therapy (FF/UMEC/VI) With 'Open' Triple Therapy (FF/VI + UMEC), in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Jul 2022
Price :
$35
*
At a glance
- Drugs Fluticasone furoate/umeclidinium/vilanterol (Primary) ; Umeclidinium; Vilanterol/fluticasone furoate
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 19 Jul 2019 Results of population pharmacokinetic analysis of pooled data from three studies(NCT02345161, NCT02164513 and NCT02729051) published in the Clinical Pharmacokinetics
- 23 May 2018 Results of population pharmacokinetic analysis from NCT02164513, NCT02345161 and NCT02729051 studies presented at the 114th International Conference of the American Thoracic Society.
- 14 Feb 2018 According to an Innoviva media release, data from this trial were included in the in the European submission of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol).